MUMBAI, July 16 (Reuters) - India has extended price caps to39 more medicines ranging from commonly used diabetes drugs toantibiotics, in the government's latest effort to improveaffordability of medicines.
The move impacts multinational drugmakers, like AbbottLaboratories and GlaxoSmithKline Plc, and anumber of local firms, including Lupin Ltd, CadilaHealthcare Ltd and Ipca Ltd, all of whomsell drugs added to the list.
A notice posted on the National Pharmaceutical PricingAuthority (NPPA) website late on Wednesday detailed the 39 newdrugs, which extend a price control list that already includesmore than 652 medicines.
New drugs added to the list include commonly usedantibiotics such as azithromycin, combinations of metformin fordiabetes, as well as the anti-emetic domperidone. (Reporting by Zeba Siddiqui in Mumbai; Editing by ClaraFerreira Marques)